ClinicalTrials.gg
CompletedNCT00372853Updated Jun 6, 2012

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

A Phase 1 interventional study of CP-675,206 and SU011248 in Carcinoma, Renal Cell, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Carcinoma, Renal Cell by AstraZeneca — 2 open to participants now, 7 under way, 2 of them phase 3. Carcinoma, Renal Cell · AstraZeneca.

Enrollment
10th of 12
28 · median 64
Started
2006
the only one that year
Phase 1
5 of 15
none open now
Registered
2nd of 15
by date

Among the 15 studies in Carcinoma, Renal Cell by AstraZeneca, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 1, and was the 2nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

2 of the 15 studies in Carcinoma, Renal Cell by AstraZeneca are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Carcinoma, Renal Cell by AstraZeneca, or all of them as a file.
02

Study summary

This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

03

Conditions studied

  • Carcinoma, Renal Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven renal cell carcinoma with
  • (ECOG) PS of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with more than one systemic therapy for renal cell carcinoma
  • History of or known , spinal cord compression or carcinomatous meningitis, or new evidence of brain or on screening Computed Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: CP-675,206 · Drug: SU011248

  • Experimental
    Arm B

    Drug: CP-675,206 · Drug: SU011248

Interventions

  • CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.

  • SU011248 administered at a dose of 37.5mg/day every day.

  • CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.

  • SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.

06

What researchers measure

Primary outcomes

  1. To determine the highest tolerable dose of CP-675,206 that can be combined with SU011248. The safety observation period will be 6 weeks from the first dose of study drug

    Time frame: 6 weeks after first dose

Secondary outcomes

  1. To allow for the possibility of genotyping should an unexpected outcome or an increase in unexplained adverse events be reported

    Time frame: 18 months

  2. To evaluate the pharmacokinetics (PK) of CP-675,206 and SU011248 when given in combination

    Time frame: up to 18 months

  3. To monitor for an antibody response to CP-675,206

    Time frame: up to 18 months

  4. To assess any preliminary evidence of anti-tumor activity: 6-18 months after last subject enrolled

    Time frame: 6-18 months after last subject enrolled

07

Study locations

5 sites
  • Research Site
    Scottsdale, Arizona 85258, United States
  • Research Site
    New Brunswick, New Jersey 08903, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Memphis, Tennessee 38120, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2006
First posted
Sep 7, 2006
Start
Nov 2006
Primary completionActual
May 2010
CompletionActual
May 2010
Last update
Jun 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00372853
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 7, 2006
Start date
Nov 2006
Primary completion
May 2010
Completion
May 2010
Last update
Jun 6, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion